AbbVie partners with DISCO on up to $2.5‑$2.54 billion bispecific cancer collaboration
+1 new source since this summary was written
DISCO Pharmaceuticals and AbbVie announced a strategic partnership on November 19, 2026 to discover and develop AND‑gated bispecific therapeutics for solid tumors. DISCO will receive a $40 million upfront cash payment and may earn milestone payments and royalties if the programs advance. AbbVie obtains an exclusive option to license any selected programs that emerge from the collaboration.
Why it matters
The deal gives AbbVie early‑stage access to DISCO’s bispecific platform, potentially expanding its oncology pipeline, while providing DISCO with significant upfront funding and the prospect of future milestone cash and royalty streams.
Key facts
- 1DISCO Pharmaceuticals and AbbVie announced a strategic collaboration on November 19, 2026. finance.yahoo.com
- 2The partnership targets the discovery and development of AND‑gated bispecific therapeutics for solid tumors. finance.yahoo.com
- 3DISCO will receive an upfront cash payment of $40 million. finance.yahoo.com
- 4AbbVie will have an exclusive option to license selected programs that result from the research. finance.yahoo.com
- 5The collaboration combines DISCO’s DISCOtech surfaceome‑mapping platform with AbbVie’s oncology research expertise. finance.yahoo.com
- 6Tiered royalties will be paid on worldwide net sales of any products that arise from the collaboration. finance.yahoo.com
Summary written by AlphAI AI Desk from 12 of 12 sources. Not investment advice. Figures are as stated by the linked sources.